Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 355, Issue 3, 2007, Pages 700-706

  Riedemann, Johann ^a   Sohail, Muhammad ^b   Macaulay, Valentine M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Co targeting; EGFR; IGF1R; shRNA; siRNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE 4; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SOMATOMEDINS; STAT5 TRANSCRIPTION FACTOR;

EID: 33847284924     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.02.041     Document Type: Article

References (24)

1. Hortobagyi G.N. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353 (2005) 1734-1736
2. Ward C.W., Garrett T.P., McKern N.M., Lou M., Cosgrove L.J., Sparrow L.G., Frenkel M.J., Hoyne P.A., Elleman T.C., Adams T.E., Lovrecz G.O., Lawrence L.J., and Tulloch P.A. The three dimensional structure of the type I insulin-like growth factor receptor. Mol. Pathol. 54 (2001) 125-132
3. Werner H., and Roberts Jr. C.T. The IGFI receptor gene: a molecular target for disrupted transcription factors. Genes Chromosomes Cancer 36 (2003) 113-120
4. Vincent A.M., and Feldman E.L. Control of cell survival by IGF signaling pathways. Growth Horm. IGF Res. 12 (2002) 193-197
5. Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62 (2002) 200-207
6. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., Zakowski M.F., Kris M.G., Ladanyi M., and Miller V.A. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12 (2006) 839-844
7. Bohula E.A., Salisbury A.J., Sohail M., Playford M.P., Riedemann J., Southern E.M., and Macaulay V.M. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J. Biol. Chem. 278 (2003) 15991-15997
8. Rochester M.A., Riedemann J., Hellawell G.O., Brewster S.F., and Macaulay V.M. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 12 (2005) 90-100
9. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
10. Miller B.S., and Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 65 (2005) 10123-10127
11. Macaulay V.M., Salisbury A.J., Bohula E.A., Playford M.P., Smorodinsky N.I., and Shiloh Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 20 (2001) 4029-4040
12. Yeh A.H., Bohula E.A., and Macaulay V.M. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene (2006)
13. Marmor M.D., Skaria K.B., and Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 903-913
14. Mattila E., Pellinen T., Nevo J., Vuoriluoto K., Arjonen A., and Ivaska J. Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. Nat. Cell Biol. 7 (2005) 78-85
15. Sturla L.M., Amorino G., Alexander M.S., Mikkelsen R.B., Valerie K., and Schmidt-Ullrichr R.K. Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. J. Biol. Chem. 280 (2005) 14597-14604
16. Biscardi J.S., Maa M.C., Tice D.A., Cox M.E., Leu T.H., and Parsons S.J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 274 (1999) 8335-8343
17. Emlet D.R., Moscatello D.K., Ludlow L.B., and Wong A.J. Subsets of epidermal growth factor receptors during activation and endocytosis. J. Biol. Chem. 272 (1997) 4079-4086
18. Okabayashi Y., Kido Y., Okutani T., Sugimoto Y., Sakaguchi K., and Kasuga M. Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. J. Biol. Chem. 269 (1994) 18674-18678
19. Okutani T., Okabayashi Y., Kido Y., Sugimoto Y., Sakaguchi K., Matuoka K., Takenawa T., and Kasuga M. Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. J. Biol. Chem. 269 (1994) 31310-31314
20. Roudabush F.L., Pierce K.L., Maudsley S., Khan K.D., and Luttrell L.M. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J. Biol. Chem. 275 (2000) 22583-22589
21. El-Shewy H.M., Kelly F.L., Barki-Harrington L., and Luttrell L.M. Ectodomain shedding-dependent transactivation of epidermal growth factor receptors in response to insulin-like growth factor type I. Mol. Endocrinol. 18 (2004) 2727-2739
22. Goetsch L., Gonzalez A., Leger O., Beck A., Pauwels P.J., Haeuw J.F., and Corvaia N. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 113 (2005) 316-328
23. Steinbach J.P., Eisenmann C., Klumpp A., and Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem. Biophys. Res. Commun. 321 (2004) 524-530
24. Janicke R.U., Sprengart M.L., Wati M.R., and Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273 (1998) 9357-9360